|
|
Vaccine Detail
|
Multi-epitope melanoma peptide vaccine |
| Vaccine Information |
- Vaccine Name: Multi-epitope melanoma peptide vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: tyrosinase/gp100/MAGE-3 and human leukocyte antigen (HLA) class I A1, A3 or A11 and B44 (NCT00085189)
- Immunization Route: subcutaneous injection
- Description: This is a peptide cancer vaccine consisting of a combination of peptides derived form several melanoma epitopes. Vaccination with multi-epitope melanoma peptide vaccine stimulates the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing the corresponding antigens, resulting in tumor cell lysis. This vaccine may stimulate a broader CTL response compared to single-antigen vaccines. (NCIT_C38695) Vaccines made from melanoma peptides or antigens may help the body build an effective immune response to kill tumor cells in patients with stage IIC-IV melanoma. This vaccine is a tyrosinase/gp100/MAGE-3 class I peptide vaccine combined with Montanide ISA 51 or ISA 51 VG with CpG adjuvant 7909 in human leukocyte antigen (HLA) class I A1, A3 or A11 and B44 matched patients with surgically resected stages IIC, III and IV melanoma. (NCT00085189)
|
| Host Response |
|
|
| References |
NCIT_C38695: Multi-epitope Melanoma Peptide Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C38695]
NCT00085189: Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma [https://clinicaltrials.gov/study/NCT00085189]
|
|
